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Summary HLA associations were observed in unrelated Malay patients with nasopharyngeal carcinoma
(NPC). HLA-B18 was observed in 18/45 (40%) Malay NPC patients compared to 22/167 (13%) Malay
normals (P=0.0001; Pc=0.0027, RR=4.4). The frequency of HLA-B17, one of the antigens associated with
Chinese NPC, was also increased among Malay NPC (13/45 29%) compared to controls (18/167 11%;
P=0.003, Pc=0.07 RR=3.4). Similar to the findings among Chinese NPC, the frequency of B17 was higher
in early onset (. 30 years) Malay NPC resulting in a higher relative risk (RR=5.0).
Nasopharyngeal carcinoma (NPC) is a
geographically restricted tumour that has attracted
considerable attention recently because of the
unique opportunity to study the genetic and
environmental factors in the pathogenesis of this
tumour. Implicated environmental factors include
the Epstein Barr virus, nitrosamine and plant
extracts (Prasad et al., 1983). The data of different
incidences among different populations, incidence
among migrants and family clustering suggested the
involvement of genetic factors in addition to
environmental factors.
HLA associations have been reported in NPC.
With the highest incidence populations, similar
HLA associations have been reported among the
Chinese from Singapore (Simons et al., 1976; Chan
et al., 1983) Malaysia, Hong Kong (Simons et al.,
1977), China (Cui & Lin, 1982) and California (Jing
et al., 1977). In Singapore, the associations among
Chinese NPC were with A2 BW46 among older
onset NPC and AW19 B17 among total NPC but
this association was especially strong among
younger onset NPC (Chan et al., 1983). Among the
mid-incidence populations, reports of HLA
associations have been inconsistent. HLA-A29 was
associated with NPC among East African Blacks
(RR= 19.5; Hall et al., 1982). Among North
African NPC, the frequencies of A3, B5 and B15
were increased and AW33, B14 and DR4 decreased
(Herait et al., 1983) and yet in another North
African population, the Tunisians, no HLA
association was found (Betuel et al., 1975). Among
low incidence populations, reports of HLA
associations in NFC were equally mixed. An
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increase in the frequencies of A3 and B5 was
observed among German NPC (Kruger et al.,
1981), A3 among NPC from Australia (Simons &
Shanmugaratnam, 1982) while no associations was
reported in other Caucasian populations (Jing et
al., 1977; Moore et al., 1983; Beigel et al., 1983). In
South East Asia, besides the high NPC incidence
Chinese population, there are ethnic groups with
mid range incidence of NPC and here we report
that results of HLA typing in NPC from one such
ethnic group, the Malays.
Materials and methods
Subjects
A total of 45 unrelated Malay NPC patients and
167 unrelated Malay normal controls was studied.
The patients attended the Ear, Nose and Throat
Departments of the Singapore General Hospital,
Singapore and the University Hospital, Kuala
Lumpur. Most of the patients were bled within 1.5
years after diagnosis but some had survived for
varying periods (1.5 to 8 years) at the time of
bleeding. The patients could be divided into early
(<30 years of age) onset or late (>30 years) onset
groups at the time of diagnosis. There were 8 early
and 37 late onset patients. The controls were
normal Malays and consisted of 106 Malays
reported previously (Chan et al., 1978) and an
additional 61 who were the normal spouses of
Malay renal patients (live transplantation program)
from Singapore and Malaysia.
HLA typing
Lymphocyte separation and HLA typing were
performed from freshly drawn venous blood as
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discussed previously (Simons et al., 1976). The
panel of antisera used to define the 26 locus A and
B antigens consisted of over 200 sera of Malay,
Chinese, Japanese, Filipino and Caucasian in
origin. Antigens of the C and DR locus were not
typed for. The significance of the difference in
antigen frequencies between patients and controls
was calculated by the Fisher's exact P-value and
this value was multiplied by the number of antigens
typed for (26) to give the corrected P(Pc) value.
The relative risk (RR) was calculated by the odds
ratio in the classical 2x2 table (Breslow & Day,
1980). If a, b, c, d represented patients with
marker, patients without marker, controls with
marker and controls without marker respectively,
the relative risk was calculated as a xd divided by
b xc.
Results
The HLA locus A and B antigen frequencies of the
total NPC patients, patient subgroups and normal
controls are shown in Table I. Compared to
controls, total Malay NPC patients had a higher
frequency of B17 and B18 and a lower frequency of
All, B15 and B40. There was no increase in the
frequency of BW46, one of the antigens found to
be associated with Chinese NPC. All the B17 in this
study was of the split BW58. Similarily all B17 in
the Chinese is also BW58. However, for ease of
comparison between this study and previously
published Chinese data where only B17 was defined
we have retained the definition of B17.
HLA-B18 was.observed in 18/45 (40%; Table II)
NPC patients compared to 22/167 (13%) controls
(x2=16.7; P=0.0001, Pc=0.0027; relative
Table II HLA antigen frequencies of Malay NPC
patients and controls
NPC Control
Antigen n=45 n= 167 P Pc RR
B18 18a (40%) 22 (13%) 0.0001 0.0027 4.4
B17 13 (29%) 18 (11%) 0.003 0.07 3.4
B40 3 (7%) 37 (22%) 0.009 NS 0.25
B15 12 (27%) 74(44%) 0.014 NS 0.46
aNumber (%)
P- by Fisher's exact test
Pc - corrected P value (P x26)
RR - relative risk
Table I HLA antigen frequencies in Malay NPC patients and
controls
Early onset Late onset Total NPC Normals
n=8 n=37 n=45 n= 167
No. Freq. No. Freq. No. Freq. No. Freq.
Al 0 - 3 0.081 3 0.067 11 0.066
A2 4 0.500 9 0.243 13 0.289 56 0.335
A3 0 1 0.027 1 0.022 4 0.024
A9 7 0.875 22 0.595 29 0.644 106 0.635
AlO 0 2 0.054 2 0.044 23 0.138
All 0 - 10 0.270 10 0.222 55 0.329
A28 0 - 0 - 0 1 0.006
A29 0 - 0 - 0 0
AW19 1 0.125 11 0.297 12 0.267 34 0.204
B5 2 0.250 4 0.108 6 0.133 25 0.150
B7 0 - 1 0.027 1 0.022 12 0.072
B8 0 - 2 0.054 2 0.044 0
B12 0 - 4 0.108 4 0.089 20 0.120
B13 0 - 3 0.081 3 0.067 14 0.084
B14 0 - 0 - 0 0
B15 2 0.250 10 0.270 12 0.267 74 0.443
B17 3 0.375 10 0.270 13 0.289 18 0.108
B18 3 0.375 15 0.405 18 0.400 22 0.132
B27 0 - 4 0.108 4 0.089 18 0.108
B37 0 0 - 0 2 0.012
B40 1 0.125 2 0.054 3 0.067 37 0.222
BW16 0 - 8 0.216 8 0.178 19 0.114
BW21 0 0 - 0 5 0.030
BW22 0 1 0.027 1 0.022 5 0.030
BW35 3 0.375 7 0.189 10 0.222 41 0.246
BW46 0 - 1 0.027 1 0.022 4 0.024HLA AND NPC IN MALAYS 391
risk =4.4). This difference was still significant after
correction for the number of antigens (26) typed
for. The frequency of B17 was significantly higher
in NPC patients (13/45, 29%) than in controls
(18/167, 11%; P=0.003, Pc=0.07; RR=3.4).
However the corrected P value just failed to reach
significance. The frequencies of B40 and B15 were
significantly lower among NPC patients compared
to controls but both these differences were not
significant when corrected.
Old vs young onset NPC
In Chinese NPC, there was differences in the HLA
associations in early and late onset patients. BW46
was associated only with late onset (>30 years)
patients whereas B17 was associated in total
patients but particularly in early onset (_ 30 years)
patients (Chan et al., 1983). In this study, early
onset (_30 years) Malay patients had higher
frequencies of A2, A9 and B17 and lower
frequencies of All compared to late onset patients
or to normals (Table I). It is interesting to note
that the finding of a higher frequency of B17
among early onset patients observed among the
Chinese was also present in the Malays. The
frequency of B17 was higher in early onset patients
and this reflected in the higher relative risk (5.0;
Table III) compared to total patients (RR=3.4).
HLA-A1 1 was not detected among early onset
patients and the decreased frequency of B40 seen in
total patients was even more marked among the
late onset patients (P =0.009; RR =0.2; Table III).
Table III HLA
Discussion
This study indicates HLA associations in Malay
NPC. The associations were with B18 and B17. The
association with B18 was significant even after
correction for the number of antigens typed for but
with Bl7 the corrected P value just failed to be
significant. B17 is also one of the antigens
associated with Chinese NPC. Among Chinese
NPC the frequency of B17 was lower in long term
survivors compared to newly diagnosed patients
(Chan et al., 1981). Unfortunately in this study we
did not have sufficient patients to make this
comparison and the frequency of B17 could be even
higher if only newly diagnosed patients were
studied. Among the Chinese, the frequency of B17
was higher in early onset patients and this study
showed a similar relationship in Malay NPC.
The frequency of B40 and B15 were lower among
the patients compared to controls and the
frequency of B40 was even slightly lower in late
onset patients. However it could not be determined
whether there was a specific decrease in these
antigen frequencies or whether the decrease was a
compensation for the increases in the frequencies of
B18 and B17.
The present findings supported the hypothesis
that genes are important in the pathogenesis of
NPC and some of these genes are associated with
the major histocompatibility complex. There are
certain similar findings between Malay and Chinese
NPC - the association with B17, the high frequency
of B17 among early onset compared to late onset
antigen frequencies in NPC patient subgroups
and controls
Nasopharyngeal carcinoma
Early onset Late onset Total Controls
Antigen n=8 n=37 n=45 n= 167
B18 Freq. 37.5% 40.5% 40.4% 13.2%
pa 0.06 0.0002 0.0001
Pca NS 0.0055 0.0027
RRa 4.0 4.5 4.4
B17 Freq. 37.5% 27.0% 28.9% 10.8%
P 0.048 0.008 0.003
Pc NS NS 0.07
RR 5.0 3.1 3.4
All Freq. 0 27.0% 22.2% 32.9%
P 0.03 NS NS
Pc NS NS NS
RR 0 0.7 0.6 -
B40 Freq. 12.5% 5.4% 6.7% 22.2%
P NS 0.009 0.009
Pc NS NS NS
RR 0.5 0.2 0.3
aComparison of total NPC patients or patient subgroups with
normal controls.392 S.H. CHAN et al.
patients and the decrease frequency of Al 1. This
closeness may be due in part to a strong belief that
the Malays originated from the Yunan Province in
China between 2500-1500BC as evidenced by their
quadrangular adze culture and unglazed cord-
marked pottery which have been traced from China
southwards (Omar, 1983). However these findings
will have to be confirmed by a larger study.
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